Bicycle Therapeutics (BCYC) Stock Forecast & Price Target

Compare

401 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BCYC Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Bicycle

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BCYC Stock 12 Month Forecast

Average Price Target

$22.29

▲(237.73% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $22.29 with a high forecast of $44.00 and a low forecast of $11.00. The average price target represents a 237.73% change from the last price of $6.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","45":"$45","15.75":"$15.75","25.5":"$25.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.75,25.5,35.25,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.07,10.833846153846153,13.597692307692308,16.361538461538462,19.125384615384615,21.889230769230767,24.653076923076924,27.416923076923077,30.18076923076923,32.94461538461538,35.708461538461535,38.472307692307695,41.23615384615385,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.07,9.163846153846155,10.257692307692308,11.35153846153846,12.445384615384615,13.53923076923077,14.633076923076922,15.726923076923075,16.82076923076923,17.914615384615384,19.00846153846154,20.10230769230769,21.196153846153845,{"y":22.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.07,8.295384615384616,8.52076923076923,8.746153846153847,8.971538461538461,9.196923076923078,9.422307692307692,9.647692307692308,9.873076923076923,10.098461538461539,10.323846153846153,10.54923076923077,10.774615384615384,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$44.00

Average Price Target$22.29

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Swayampakula Ramakanth

H.C. Wainwright

$33

Buy

400.00%

Upside

Reiterated

10/31/25

Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments

Ami Fadia

Needham

$28

Buy

324.24%

Upside

Reiterated

10/31/25

Strategic Regulatory Alignment and Positive Momentum Justify Buy Rating for Bicycle TherapeuticsWe this makes sense, given the evolving regulatory and commercial model for drugs across the globe. Not to mention the incidence of bladder cancer is higher in EU vs US (~200K vs ~80K). Most importantly, since mtg is moving forward with seeking regulatory feedback, we view that as a positive readthrough for how the data are progressing, which is probably what drove the positive move in the stock yesterday. We update our model for the quarter and reiterate Buy.

Jay Olson

Oppenheimer

$44

Buy

566.67%

Upside

Reiterated

10/31/25

Oppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)

Maxwell Skor

Morgan Stanley

$13

Hold

96.97%

Upside

Reiterated

10/31/25

Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Bicycle Therapeutics (BCYC)Bicycle Therapeutics Plc Equal-Weight with price target unchanged at 13.00.

Peter Lawson

Barclays

$15

Buy

127.27%

Upside

Reiterated

10/31/25

Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Reni Benjamin

Citizens JMP

$10→$12

Buy

81.82%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Leonid Timashev

RBC Capital

$27→$11

Hold

66.67%

Upside

Downgraded

10/30/25

Bicycle Therapeutics downgraded to Sector Perform at RBC CapitalBicycle Therapeutics downgraded to Sector Perform at RBC Capital

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

10/30/25

TD Cowen Remains a Buy on Bicycle Therapeutics (BCYC)

Jonathan Chang

Leerink Partners

$24

Buy

263.64%

Upside

Reiterated

08/11/25

Leerink Partners Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Kalpit Patel

B. Riley Securities

$17→$14

Hold

112.12%

Upside

Reiterated

05/02/25

B.Riley Financial Sticks to Their Hold Rating for Bicycle Therapeutics (BCYC)

Kelly Shi

Jefferies

$42

Buy

536.36%

Upside

Reiterated

02/25/25

Bicycle Therapeutics: Promising Clinical Advances and Strong Financial Position Support Buy RatingWe believe the data support its unique MOA w/ small peptide radioligands. Co will report add'l MT1-MMP human imaging data in mid'25 and initial EphA2 human imaging data in 2H25. BCYC aims to start the first clinical trial for its first BRC program in 2026. Q4'24 Financials. As of 12/31/24, co had $879.5M in cash and cash equivalents to provide runway into 2H27.

Anthony Butler

Rodman & Renshaw

$33

Buy

400.00%

Upside

Reiterated

02/25/25

Rodman Renshaw reiterates Buy Rating on Bicycle Therapeutics (BCYC)Rodman Renshaw analyst Tony Butler reiterated a Buy rating and $33.00 price target on Bicycle Therapeutics (NASDAQ: BCYC)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Swayampakula Ramakanth

H.C. Wainwright

$33

Buy

400.00%

Upside

Reiterated

10/31/25

Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments

Ami Fadia

Needham

$28

Buy

324.24%

Upside

Reiterated

10/31/25

Jay Olson

Oppenheimer

$44

Buy

566.67%

Upside

Reiterated

10/31/25

Oppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)

Maxwell Skor

Morgan Stanley

$13

Hold

96.97%

Upside

Reiterated

10/31/25

Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Bicycle Therapeutics (BCYC)Bicycle Therapeutics Plc Equal-Weight with price target unchanged at 13.00.

Peter Lawson

Barclays

$15

Buy

127.27%

Upside

Reiterated

10/31/25

Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Reni Benjamin

Citizens JMP

$10→$12

Buy

81.82%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Bicycle Therapeutics (NASDAQ: BCYC) and Foghorn Therapeutics (NASDAQ: FHTX)

Leonid Timashev

RBC Capital

$27→$11

Hold

66.67%

Upside

Downgraded

10/30/25

Bicycle Therapeutics downgraded to Sector Perform at RBC CapitalBicycle Therapeutics downgraded to Sector Perform at RBC Capital

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

10/30/25

TD Cowen Remains a Buy on Bicycle Therapeutics (BCYC)

Jonathan Chang

Leerink Partners

$24

Buy

263.64%

Upside

Reiterated

08/11/25

Leerink Partners Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

Kalpit Patel

B. Riley Securities

$17→$14

Hold

112.12%

Upside

Reiterated

05/02/25

B.Riley Financial Sticks to Their Hold Rating for Bicycle Therapeutics (BCYC)

Kelly Shi

Jefferies

$42

Buy

536.36%

Upside

Reiterated

02/25/25

Anthony Butler

Rodman & Renshaw

$33

Buy

400.00%

Upside

Reiterated

02/25/25

Rodman Renshaw reiterates Buy Rating on Bicycle Therapeutics (BCYC)Rodman Renshaw analyst Tony Butler reiterated a Buy rating and $33.00 price target on Bicycle Therapeutics (NASDAQ: BCYC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bicycle Therapeutics

1 Month

xxx

Success Rate

9/24 ratings generated profit

Average Return

-4.70%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of -4.70% per trade.

3 Months

xxx

Success Rate

14/32 ratings generated profit

Average Return

-3.32%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of -3.32% per trade.

1 Year

Jonathan ChangLeerink Partners

Success Rate

8/24 ratings generated profit

Average Return

-19.77%

reiterated a buy rating 3 months ago

Copying Jonathan Chang's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -19.77% per trade.

2 Years

xxx

Success Rate

4/29 ratings generated profit

Average Return

-36.17%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.79% of your transactions generating a profit, with an average return of -36.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCYC Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BCYC has received 6 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. BCYC average Analyst price target in the past 3 months is 22.29.

Each month's total comprises the sum of three months' worth of ratings.

BCYC Financial Forecast

BCYC Earnings Forecast

Next quarter’s earnings estimate for BCYC is -$0.94 with a range of -$1.18 to -$0.79. The previous quarter’s EPS was -$0.85. BCYC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BCYC has Performed in-line its overall industry.

BCYC Sales Forecast

Next quarter’s sales forecast for BCYC is $7.32M with a range of $2.92M to $15.00M. The previous quarter’s sales results were $11.66M. BCYC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BCYC has Performed in-line its overall industry.

BCYC Stock Forecast FAQ

What is BCYC’s average 12-month price target, according to analysts?

Based on analyst ratings, Bicycle Therapeutics Ltd’s 12-month average price target is 22.29.

What is BCYC’s upside potential, based on the analysts’ average price target?

Bicycle Therapeutics Ltd has 237.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BCYC a Buy, Sell or Hold?

Bicycle Therapeutics Ltd has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Bicycle Therapeutics Ltd’s price target?

The average price target for Bicycle Therapeutics Ltd is 22.29. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $44.00 ,the lowest forecast is $11.00. The average price target represents 237.73% Increase from the current price of $6.6.

What do analysts say about Bicycle Therapeutics Ltd?

Bicycle Therapeutics Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of BCYC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bicycle Therapeutics (BCYC) Stock Forecast & Price Target

BCYC Analyst Ratings

BCYC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bicycle Therapeutics

BCYC Analyst Recommendation Trends

BCYC Financial Forecast

BCYC Earnings Forecast

BCYC Sales Forecast

BCYC Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts